D. E. Shaw & Co., Inc. Terns Pharmaceuticals, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding TERN
# of Institutions
118Shares Held
61MCall Options Held
155KPut Options Held
48.3K-
Orbimed Advisors LLC San Diego, CA7.62MShares$57.4 Million1.13% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.66MShares$50.1 Million5.84% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$45.9 Million1.32% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.43MShares$25.8 Million0.01% of portfolio
-
Vr Adviser, LLC New York, NY3.41MShares$25.7 Million1.92% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $283M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...